Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01148498
First received: June 18, 2010
Last updated: September 18, 2012
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2012
  Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 18, 2012